Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Myelodysplastic Syndromes 2Melanoma 2Leukemia, Prolymphocytic, T-Cell 2Hodgkin Disease 2Solid Tumors 1Sarcoma, Synovial 1Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Myeloproliferative Disorders 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lung Neoplasms 1Liposarcoma, Myxoid 1Leukemia, Plasma Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Graft vs Host Disease 1Endometrial Neoplasms 1Colorectal Neoplasms 1Chondrosarcoma 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 10fludarabine 6Doxorubicin 3tazemetostat 2sargramostim 2pembrolizumab 2fludarabine phosphate 2Radiotherapy 2Radiation 2ribociclib 1poly ICLC 1peposertib 1pegfilgrastim 1liposomal doxorubicin 1itacitinib 1cixutumumab 1baricitinib 1aldesleukin 1Specimen Handling 1Rifampin 1Nivolumab 1Magnetic Resonance Spectroscopy 1Itraconazole 1Immunotherapy, Adoptive 1Immune Checkpoint Inhibitors 1Ifosfamide 1INCB039110 1Filgrastim 1Dehydroepiandrosterone 1Decitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Sarcoma, Synovial × itacitinib × Clear all
NCT03670069 2024-05-08

Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas

Fred Hutchinson Cancer Center

Phase 1 Terminated
27 enrolled
Sarcoma

Chondrosarcoma, Leiomyosarcoma, Sarcoma, Sarcoma, Synovial, Liposarcoma, Myxoid, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡